Racial Differences in Diabetic Cardiomyopathy, Genetics of HCM, Semaglutide vs. Tirzepatide for Weight Loss

In this week’s View, Dr. Eagle looks at the ARISE-HF trial that examined racial differences in diabetic cardiomyopathy. He then explores established and emerging implications of treatment of genetic hypertrophic cardiomyopathy (HCM). Finally, Dr. Eagle discusses the use of GLP-1 agonists, including semaglutide vs. tirzepatide for weight loss in adults with overweight or obesity. 

 Subscribe to Eagle’s Eye View